1. Implantable Cardioverter Defibrillator and Resynchronization Therapy in Patients With Overt Chronic Kidney Disease: JACC State-of-the-Art Review.
- Author
-
Varga CR, Cleland JGF, Abraham WT, Lip GYH, Leyva F, and Hatamizadeh P
- Subjects
- Humans, Cardiac Resynchronization Therapy methods, Defibrillators, Implantable, Renal Insufficiency, Chronic therapy, Renal Insufficiency, Chronic complications, Heart Failure therapy
- Abstract
Heart failure and chronic kidney disease are common and clinically important conditions that regularly coexist. Electrophysiologic changes of advanced heart failure often result in abnormal conduction, causing dyssynchronous contraction, and development of ventricular arrhythmias, which can lead to sudden cardiac arrest. In the last 2 decades, implantable cardioverter-defibrillator and cardiac resynchronization therapy devices have been developed to address these complications. However, when the coexisting chronic kidney disease is advanced, the associated pathophysiologic cardiovascular changes can alter the efficacy and safety of those interventions and complicate the management. This review explores the impact of comorbid advanced heart failure and advanced chronic kidney disease on the efficacy and safety of implantable cardioverter-defibrillator and cardiac resynchronization therapy, the currently available evidence, and potential future directions., Competing Interests: Funding Support and Author Disclosures Dr Cleland has received research grants from Bristol Myers Squibb, CSL-Vifor, and Pharmacosmos; and has received honoraria for advisory boards and speaking from Biopeutics, Boehringer Ingelheim, Bristol Myers Squibb, CSL-Vifor, and Pharmacosmos. Dr Abraham has received personal fees from Medtronic and Abbott. Dr Lip is a consultant and speaker for Bristol Myers Squibb/Pfizer, Boehringer Ingelheim, Daiichi-Sankyo, and Anthos, no fees are received personally; is a National Institute for Health and Care Research (NIHR) Senior Investigator and coprincipal investigator of the AFFIRMO project on multimorbidity in AF, which has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 899871. Dr Hatamizadeh has served as advisory board member for Horizon Therapeutics; and receives research support from Sarfez Pharmaceutical Company. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2024. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF